Quest Diagnostics (DGX) Tops Q3 EPS by 2c; Narrows FY16 Outlook

Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $1.37, $0.02 better than the analyst estimate of $1.35. Revenue for the quarter came in at $1.89 billion versus the consensus estimate of $1.89 billion.

GUIDANCE:

Quest Diagnostics sees FY2016 EPS of $5.07-$5.12, versus prior guidance of $5.02-$5.17 and the consensus of $5.11. Quest Diagnostics sees FY2016 revenue of $7.51 billion, versus prior guidance of $7.47-7.54 billion and the consensus of $7.52 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)
• Raymond James Reiterates Underperform Rating on Lennar (LEN)